公开(公告)号：US20240228456A1

公开(公告)日：2024-07-11

申请号：US18557827

申请日：2022-06-13

Applicant: JOHNSON MATTHEY PUBLIC LIMITED COMPANY

Inventor： Johannes SCHRANCK ,  Eric SLACK

IPC: C07D401/06 ,  C07C1/207 ,  C07C41/30 ,  C07C253/30 ,  C07D213/24 ,  C07D277/22 ,  C07D307/36 ,  C07D333/10 ,  C07D403/06 ,  C07D405/06 ,  C07D409/06 ,  C07D417/06

CPC classification number: C07D401/06 ,  C07C1/2078 ,  C07C41/30 ,  C07C253/30 ,  C07D213/24 ,  C07D277/22 ,  C07D307/36 ,  C07D333/10 ,  C07D403/06 ,  C07D405/06 ,  C07D409/06 ,  C07D417/06

Abstract: The invention relates to a process for synthesising organic molecules. The invention provides a process for forming an sp2-sp3 carbon-carbon bond between a first compound comprising a substituted or unsubstituted aromatic group and a second compound comprising a substituted or unsubstituted aromatic group in the presence of a catalyst, water, and a first base. The process may find use in the preparation of active pharmaceutical ingredients.

公开(公告)号：US11851443B2

公开(公告)日：2023-12-26

申请号：US17579457

申请日：2022-01-19

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Roland Gendron ,  Melissa Fleury ,  Adam D. Hughes

IPC: C07D498/08 ,  C07D213/81 ,  C07D231/14 ,  C07D233/26 ,  C07D233/90 ,  C07D237/24 ,  C07D239/34 ,  C07D241/24 ,  C07D249/04 ,  C07D249/10 ,  C07D249/18 ,  C07D257/04 ,  C07D261/20 ,  C07D263/34 ,  C07D271/06 ,  C07D277/56 ,  C07D307/68 ,  C07D333/70 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/12 ,  C07D409/06 ,  C07D471/04 ,  C07D498/04 ,  C07D261/18 ,  C07D207/34 ,  C07D239/36 ,  C07D413/06 ,  A61K31/42 ,  A61K31/422 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/04 ,  C07D413/12 ,  C07D213/79 ,  C07D213/80 ,  C07D237/04 ,  C07D249/08 ,  C07D249/12 ,  C07D261/12 ,  C07D263/56 ,  C07D277/46 ,  C07D333/40

CPC classification number: C07D498/08 ,  A61K31/42 ,  A61K31/422 ,  A61K31/5377 ,  A61K45/06 ,  C07D207/34 ,  C07D213/79 ,  C07D213/80 ,  C07D213/81 ,  C07D231/14 ,  C07D233/26 ,  C07D233/90 ,  C07D237/04 ,  C07D237/24 ,  C07D239/34 ,  C07D239/36 ,  C07D241/24 ,  C07D249/04 ,  C07D249/08 ,  C07D249/10 ,  C07D249/12 ,  C07D249/18 ,  C07D257/04 ,  C07D261/12 ,  C07D261/18 ,  C07D261/20 ,  C07D263/34 ,  C07D263/56 ,  C07D271/06 ,  C07D277/46 ,  C07D277/56 ,  C07D307/68 ,  C07D333/40 ,  C07D333/70 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/12 ,  C07D409/06 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D471/04 ,  C07D498/04

Abstract: In one aspect, the invention relates to compounds having the formula:




where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

公开(公告)号：US20230373983A1

公开(公告)日：2023-11-23

申请号：US18319560

申请日：2023-05-18

Applicant: AstraZeneca AB

Inventor： Daniel Tor PETTERSEN ,  Stéphanie Marcelle GUERET ,  Nidhal SELMI ,  Erik Lars MALMERBERG ,  Tord Bertil INGHARDT ,  Jan Åke LINDBERG ,  Jens Peter BRANDT ,  Jon Paul JANET ,  Björn Erik Anton HOLM

IPC: C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D413/04 ,  C07D487/04 ,  C07D471/04 ,  C07D409/06 ,  C07D271/06 ,  C07D498/10

CPC classification number: C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D413/04 ,  C07D487/04 ,  C07D471/04 ,  C07D409/06 ,  C07D271/06 ,  C07D498/10

Abstract: The specification relates to compounds of Formula (I):




and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of diseases such as liver disease.

公开(公告)号：US20230365582A1

公开(公告)日：2023-11-16

申请号：US18042352

申请日：2021-08-20

Applicant: KANAPH THERAPEUTICS INC. ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Young Sook SHIN ,  Sang Kyun LIM ,  Yeri LEE ,  Donggeon KIM ,  Soo Bong HAN ,  Chang Soo YUN ,  Hyun Jin KIM ,  Joo Youn LEE ,  Hyuk LEE ,  Sikwang SEONG

IPC: C07D495/04 ,  C07D333/24 ,  C07D333/38 ,  C07D409/10 ,  C07D409/06

CPC classification number: C07D495/04 ,  C07D333/24 ,  C07D333/38 ,  C07D409/10 ,  C07D409/06

Abstract: The present application relates to a novel compound having inhibitory activity on prostaglandin E2 receptor and uses thereof, and provides a compound represented by formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a method of using the same.

公开(公告)号：US20230331710A1

公开(公告)日：2023-10-19

申请号：US18040966

申请日：2021-08-05

Applicant: SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD

Inventor： Linbo LUAN ,  Yongkai CHEN ,  Chaodong WANG

IPC: C07D405/06 ,  C07D471/04 ,  C07D417/06 ,  C07D413/06 ,  C07D409/06 ,  C07D405/14 ,  C07D401/06 ,  C07D401/14

CPC classification number: C07D405/06 ,  C07D471/04 ,  C07D417/06 ,  C07D413/06 ,  C07D409/06 ,  C07D405/14 ,  C07D401/06 ,  C07D401/14

Abstract: A heterocyclic compound as represented by formula I, a preparation method therefor, a pharmaceutical composition comprising same and use thereof are provided. The heterocyclic compound can be used as a complement factor B inhibitor and is used for preparing a medicament for treating a disease related to abnormal activation of the complement system or occur in normal functioning of the complement system. The heterocyclic compound can be used as a therapeutic agent for a disease related to inflammation and immunity.

公开(公告)号：US20230295087A1

公开(公告)日：2023-09-21

申请号：US17610634

申请日：2020-05-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Lalgudi S. Harikrishnan ,  Brian E. Fink ,  Patrice Gill ,  Lan-Ying Qin ,  Muthoni G. Kamau ,  Tram N. Huynh ,  Ashok Vinayak Purandare ,  Honghe Wan ,  Daniel O’Malley

IPC: C07D209/60 ,  C07D409/06 ,  C07F5/02 ,  C07D403/06 ,  C07D403/10 ,  C07D401/06 ,  C07D417/06 ,  C07D413/06 ,  C07D405/12 ,  C07D403/12 ,  C07D409/12

CPC classification number: C07D209/60 ,  C07D401/06 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07F5/025 ,  C07B2200/05

Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20230242478A1

公开(公告)日：2023-08-03

申请号：US17610548

申请日：2020-05-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Lalgudi S. Harikrishnan ,  Muthoni G. Kamau ,  Brian E. Fink

IPC: C07C317/22 ,  C07D207/12 ,  C07D409/06 ,  C07D407/06 ,  C07D401/06 ,  C07D403/06 ,  C07D417/06

CPC classification number: C07C317/22 ,  C07D207/12 ,  C07D409/06 ,  C07D407/06 ,  C07D401/06 ,  C07D403/06 ,  C07D417/06

Abstract: The present invention is directed to compounds of the formula [INSERT CHEMICAL STRUCTURE HERE}] wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US11713308B2

公开(公告)日：2023-08-01

申请号：US17368738

申请日：2021-07-06

Applicant: YUHAN CORPORATION

Inventor： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Eui Chul Lee ,  Sol Park ,  Hyok Jun Cho ,  Cheol Hee Lim ,  So Young Kim ,  Hyun Ho Choi ,  Da Na Jeong ,  Na Yeon Yang ,  Na Ry Ha

IPC: C07D403/10 ,  C07D249/12 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/10 ,  C07D405/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/14

CPC classification number: C07D403/10 ,  C07D249/12 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/10 ,  C07D405/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/14

Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20230157162A1

公开(公告)日：2023-05-18

申请号：US18150450

申请日：2023-01-05

Applicant: Samsung Electronics Co., Ltd.

Inventor： Jisoo Shin ,  Yeong Suk Choi ,  Katsunori Shibata ,  Taejin Choi ,  Sungyoung Yun ,  Ohkyu Kwon ,  Sangmo Kim ,  Hiromasa Shibuya ,  Gae Hwang Lee ,  Yong Wan Jin ,  Hyesung Choi ,  Chul Baik ,  Hyerim Hong

IPC: H10K85/60 ,  C07D421/04 ,  C07F7/08 ,  C07D421/14 ,  C07F7/30 ,  C07D409/06 ,  C07D421/06 ,  C07F11/00 ,  H10K30/30 ,  H10K39/32 ,  H10K85/30 ,  H10K85/40

CPC classification number: H10K85/657 ,  C07D421/04 ,  C07F7/0816 ,  C07D421/14 ,  C07F7/30 ,  C07D409/06 ,  C07D421/06 ,  C07F11/00 ,  H10K30/30 ,  H10K39/32 ,  H10K85/30 ,  H10K85/40 ,  H10K85/615 ,  H10K85/636 ,  H10K85/649 ,  H10K85/654 ,  H10K85/655

Abstract: A compound of Chemical Formula 1, and a photoelectric device, an image sensor, and an electronic device including the same are disclosed:




In Chemical Formula 1, each substituent is the same as defined in the detailed description.

公开(公告)号：US20190209550A1

公开(公告)日：2019-07-11

申请号：US16307632

申请日：2017-06-28

Applicant: VIIV HEALTHCARE UK (NO. 5) LIMITED

Inventor： Jie CHEN ,  Nicholas A. MEANWELL ,  Alicia REGUEIRO-REN ,  Sing-Yuen SIT ,  Jacob SWIDORSKI ,  Yan CHEN

IPC: A61K31/4725 ,  A61K31/5365 ,  A61K45/06 ,  A61K31/496 ,  C07D217/06 ,  A61K31/541 ,  A61K31/53 ,  C07D417/14 ,  C07D401/12 ,  C07D417/12 ,  C07D471/04 ,  C07D473/28 ,  A61K31/522 ,  C07D405/12 ,  C07D487/04 ,  C07D495/04 ,  C07D401/14 ,  C07D413/12 ,  C07D407/12 ,  C07D471/08 ,  C07D487/08 ,  C07D453/00 ,  A61K31/4748 ,  C07D491/056 ,  A61P31/18

CPC classification number: A61K31/4725 ,  A61K31/4748 ,  A61K31/496 ,  A61K31/522 ,  A61K31/53 ,  A61K31/5365 ,  A61K31/541 ,  A61K45/06 ,  A61P31/18 ,  C07D217/06 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D407/12 ,  C07D409/06 ,  C07D409/14 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D453/00 ,  C07D471/04 ,  C07D471/08 ,  C07D473/28 ,  C07D487/04 ,  C07D487/08 ,  C07D491/056 ,  C07D495/04

Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, azadecaline derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.